Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 6;12(2):e0170634.
doi: 10.1371/journal.pone.0170634. eCollection 2017.

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer

Shinichiro Kashiwagi  1 , Yuka Asano  1 , Wataru Goto  1 , Koji Takada  1 , Katsuyuki Takahashi  2 , Satoru Noda  1 , Tsutomu Takashima  1 , Naoyoshi Onoda  1 , Shuhei Tomita  2 , Masahiko Ohsawa  3 , Kosei Hirakawa  1 , Masaichi Ohira  1
Affiliations

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer

Shinichiro Kashiwagi et al. PLoS One. .

Abstract

Background: Eribulin mesylate (eribulin) is currently indicated for treatment of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms that suppress epithelial-mesenchymal transition (EMT) of cancer cells. On the other hand, Tumor-infiltrating lymphocytes (TILs), which are considered indicators of immune response monitoring, have been reported as prognostic factors and predictors of therapeutic efficacy. We thought that eribulin, which has an EMT-inhibiting mechanism, may produce an antitumor effect by improving the immune microenvironment, and in this study investigated the effects of breast cancer eribulin chemotherapy on the immune microenvironment with TILs as a marker.

Methods: TILs was evaluated in 52 patients with MBC who underwent chemotherapy with eribulin. The correlation between TILs evaluated according to the standard method, and prognosis, including the efficacy of eribulin chemotherapy, was investigated retrospectively.

Results: Of the 52 MBC patients, 29 (55.8%) were in the high TILs group and 23 (44.2%) were in the low TILs group. The high TILs group included significantly more triple-negative breast cancer (TNBC) (p = 0.008) than the low TILs group. In an analysis of outcomes, TNBC patients in the high TILs group had significantly longer disease-free survival than TNBC patients in the low TILs group (p = 0.033, log-rank), but no significant differences were seen in all breast cancer patients (p = 0.489, log-rank) or in non-TNBC patients (p = 0.878, log-rank). In a multivariate analysis of recurrence in TNBC patients, being in the high TILs group was again an independent factor for a good outcome (p = 0.031, HR = 0.063).

Conclusion: The results of this study suggest that TILs may be useful as a predictive marker of the therapeutic effect of eribulin chemotherapy in TNBC.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Histopathologic analysis of the percentage of TILs was performed on a single full-face hematoxylin and eosin-stained tumor section.
TILs were defined as the percentage of tumor stroma containing infiltrating lymphocytes. Proportional scores were defined as 3, 2, 1, and 0 if the area of stroma with lymphoplasmacytic infiltration around invasive tumor cell nests was > 50% (A); > 10–50% (B); ≤ 10% (C); and absent (D), respectively.
Fig 2
Fig 2
In an analysis of outcomes, TNBC patients in the high TILs group had significantly longer disease-free survival than TNBC patients in the low TILs group (p = 0.033, log-rank) (A), but no significant differences were seen in all breast cancer patients (p = 0.489, log-rank) (B) or in non-TNBC patients (p = 0.878, log-rank) (C).
Fig 3
Fig 3
Among TNBC patients OS was significantly longer in the high TILs group than in the low TILs group (p = 0.042, log-rank) (A). However, no increase in OS was seen among all breast cancer patients (p = 0.668, log-rank) (B) or among non-TNBC patients (p = 0.535, log-rank) (C). With regard to TTF, no significant differences were seen in any subtype (D–F).
See this image and copyright information in PMC

References

    1. Hirata J, Katsuno M, Kaneko S, Umemura T, Nishimura J, Motomura S, et al. Clinical significance of human bone marrow stromal cell colonies in acute leukemias. Leuk Res. 1986;10(12):1441–5. Epub 1986/01/01. - PubMed
    1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–65. Epub 2004/04/02. 10.1038/nrc1317 - DOI - PubMed
    1. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64(16):5760–6. Epub 2004/08/18. 10.1158/0008-5472.CAN-04-1169 - DOI - PubMed
    1. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991;266(24):15882–9. Epub 1991/08/25. - PubMed
    1. Ledford H. Complex synthesis yields breast-cancer therapy. Nature. 2010;468(7324):608–9. Epub 2010/12/03. 10.1038/468608a - DOI - PubMed

MeSH terms